Study of short-acting, long-acting and abuse-deterrent opioid use

The mix of opioids is crucial to the cost impact of abuse-deterrent opioids

November 30, 2017

What was the study about?

With opioid use and abuse continuing to rise, plan sponsors need to use every tool at their disposal. Prime continues to identify valuable insights from years of pharmacy and medical analysis expertise.

This study looked at medical and pharmacy claims to define and divide utilization patterns, quantities, dosages and diagnoses into three separate groups:

  • Members who were only prescribed short-acting opioids
  • Members who were only prescribed long-acting opioids
  • Members who were prescribed both short- and long-acting opioids

What did we learn?

Most members who get opioids are prescribed short-acting opioids. And most of them have only one or two claims. That is consistent with prescribing guidelines.

But groups of members exist that appear to be experiencing non-typical opioid prescribing. This gives a plan sponsor thousands of members where they might intervene to improve health outcomes and increase savings.



Methods

We identified more than 1 million members (9 percent) who had at least one opioid claim (out of 12 million continuously enrolled from July 1, 2013 to Sept. 1, 2014). These members were divided into the three groups identified above. The groups were followed for 12 months. Medical claims were used to further divide them by diagnosis.

Results

Short-acting only: 94 percent (of the 9 percent) were prescribed short-acting opioids. As would be expected, nearly two thirds of these members received only one or two prescriptions. 66 percent of members received only one prescription with less than 10 pills. But 6 percent of members had 16 or more claims within 12 months. This indicates the use of short-acting opioids for long-term chronic opioid therapy.

Long-acting: Only 1 percent (of the 1 million opioid utilizers) were prescribed long-acting opioids. Just over half of these members received only one or two prescriptions. 62 percent of these members were new starts – they had no claims for opioids in the previous 120 days. It is unsafe to initiate opioid therapy with a long-acting opioid. The CDC recommends against it. 9 percent of these members had 16 or more claims within 12 months. These members are on chronic opioid therapy with only long-acting opioids. Long-acting opioid therapy should always include a short-acting opioid for break through pain. It is not recommended to be on long-acting opioid therapy only. These all represent opportunities for interventions.

Short- and long-acting: 6 percent (of the 1 million) were prescribed both short- and long-acting opioids. 54 percent of these members had 16 or more claims within 12 months. 4 percent of these members had a cancer diagnosis.

Diagnoses: Most common diagnoses for all three groups were: low back pain, joint pain and arthritis, followed by abdominal pain and headache. Percentages varied for each. The study poster includes more detail. The CDC recommends avoiding opioids for the treatment of back pain and headache.

Conclusions

GuidedHealth® interventions can target:

  • Long-acting opioid utilizers
  • Members with a large quantity of opioids in a short period of time
  • Members without evidence of diagnosis
  • A prior authorization (PA) program could help address opioid use patterns among large numbers of new starts. Potential savings for a new start PA could save $0.01 per member per month.

Additional research could focus on short- vs long-term use, and concurrent treatments – like use of benzodiazepines and opioid prescriptions.

What does this mean for you?

Prime’s Controlled Substance Management Program can help plan sponsors identify members with a variety of risk profiles, using specific claim analyses and predictive models. A range of clinical and outreach programs are available to help plan sponsors achieve savings, quality and outcomes goals.

Short-Acting Opioid Utilization Patterns Can Aid in Clinical Program Development. April 2015.

Related research

Scientific presentations

August 21, 2021

Real-world CAR-T treatment costs can range from $700,000 to $1 million

CAR-T treatment costs more than the CAR-T product itself; Prime’s real-world study of…

Scientific presentations

August 1, 2021

Prime’s analytics uncovers the hidden ups and downs behind the flat drug trend for MS DMDs

Insights from integrated medical and pharmacy claims show a big upswing in one…

Scientific presentations

June 21, 2021

Break autoimmune (AI) into indication-specific info for actionable strategy

Prime uses integrated medical and pharmacy data and breaks down largest drug category…